- Home
- RADX vs IPA Comparison
RADX vs IPA Comparison
Compare RADX & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- IPA
- Stock Information
- Founded
- RADX 2021
- IPA 1983
- Country
- RADX Australia
- IPA United States
- Employees
- RADX N/A
- IPA N/A
- Industry
- RADX
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- RADX
- IPA Health Care
- Exchange
- RADX NYSE
- IPA Nasdaq
- Market Cap
- RADX 32.5M
- IPA 30.7M
- IPO Year
- RADX N/A
- IPA 2017
- Fundamental
- Price
- RADX $4.60
- IPA $1.01
- Analyst Decision
- RADX Strong Buy
- IPA Strong Buy
- Analyst Count
- RADX 2
- IPA 2
- Target Price
- RADX $13.50
- IPA $4.00
- AVG Volume (30 Days)
- RADX 22.6K
- IPA 4.7M
- Earning Date
- RADX 02-26-2025
- IPA 07-28-2025
- Dividend Yield
- RADX N/A
- IPA N/A
- EPS Growth
- RADX N/A
- IPA N/A
- EPS
- RADX N/A
- IPA N/A
- Revenue
- RADX $204,609.00
- IPA $16,581,105.00
- Revenue This Year
- RADX N/A
- IPA $4.67
- Revenue Next Year
- RADX N/A
- IPA $14.15
- P/E Ratio
- RADX N/A
- IPA N/A
- Revenue Growth
- RADX N/A
- IPA 1.34
- 52 Week Low
- RADX $3.50
- IPA $0.27
- 52 Week High
- RADX $50.82
- IPA $1.07
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- IPA 80.49
- Support Level
- RADX N/A
- IPA $0.51
- Resistance Level
- RADX N/A
- IPA $1.04
- Average True Range (ATR)
- RADX 0.00
- IPA 0.12
- MACD
- RADX 0.00
- IPA 0.04
- Stochastic Oscillator
- RADX 0.00
- IPA 88.60
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.